The true costs of cancer in Europe revealed
The first ever estimate of the economic burden of cancer in Europe shows that it exceeds 124 billion euros
ESMO Media Releases
ESMO 2012 Press Release: Myths and misunderstandings hamper efforts to prevent cancer
Studies presented at ESMO 2012 highlight challenges of cancer prevention
Phase III MISSION trial
Sorafenib does not extend overall survival as third or fourth line therapy in lung cancer, EGFR status may help select patients who will benefit most
Studies show drug combinations effective for melanoma
Promising new data from trials aimed at delaying resistance to BRAF inhibitors
Governments failing to address “global pandemic of untreated cancer pain”
Landmark global survey reveals major shortcomings in many countries around the world
ESMO 2012 Press Release: Many cancer patients unaware of the personalised medicine revolution in oncology, survey shows
811 people surveyed by Prof Tejpar and colleagues
Will bureaucracy stifle the development of new cancer treatments?
ESMO 2012 Press Release: New weapons in the fight against cancer
Where are the most promising developments from first-in-human studies?
Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive lung cancer
Head-to-head study compares of crizotinib with standard chemotherapy in this patient group
Phase III data in treatment of renal cell carcinoma reported
New trial results on pazopanib and temsirolimus have important implications for patients
Should aspirin be used to prevent cancer?
Debate at ESMO 2012 Congress focuses on whether there is enough evidence to start using aspirin to reduce the risk of colorectal cancer